Immune-checkpoint blockade in genomically selected populations

• Module leader: IGR and VHIO
• Pharma partner: Roche

The current protocol contains the Module 1 of iBASKET with the following arms:

• Arm 1A: BRCA1 or BRCA2 mutations
• Arm 1B: MLH1, MSH2, MSH6, PMS2 mutations
• Arm 1C: tumours with POLE mutation, POLD1 mutation
• Arm 1D: hypermutated tumours
• Arm 1E: tumours with other mutations in DNA-repair genes.
• Arm 1F: tumours with amplified PDL1

Futibatinib in subjects with FGFR-aberrant solid tumours

• Module leader: VHIO
• Pharma partner: Taiho Oncology, Inc

The current protocol contains the Module 2 of iBASKET with the following arms:

• Arm 2A: Known pathogenic FGFR1-3 mutations.
• Arm 2B: Variants of unknown significance in FGFR1-3 with functional relevance or pathogenic FGFR4 mutations.
• Arm 2C: Highly amplified FGFR1-3 (NGS equivalent to FISH ratio > 6) WITH high FGFR1-3 mRNA (above the percentile 95 for general cancer population by using Nanostring Gene expression profile in solid tumours (with the exception of gastric and breast cancer).
• Arm 2D: Highly amplified FGFR1-3 (NGS equivalent to FISH ratio >6) WITHOUT high FGFR1-3 mRNA (above the percentile 95 for general cancer population by using Nanostring Gene expression profile in solid tumours (with the exception of gastric and breast cancer).